Welcome to our dedicated page for Genius Sports SEC filings (Ticker: GENI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Genius Sports's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Genius Sports's regulatory disclosures and financial reporting.
Genius Sports (GENI) insider Jack Davison filed a notice of proposed stock sales under Rule 144. The filing covers the planned sale of 177,897 shares of common stock through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $1,930,040.13, at a time when 214,097,454 shares were outstanding. These shares were acquired on 01/05/2026 via restricted stock vesting from the issuer as compensation, with the same date listed for payment. The filing also notes prior sales by Davison over the past three months, including 400,673 common shares sold on 11/10/2025 for gross proceeds of $4,167,039.27 and 202,876 common shares sold on 01/05/2026 for gross proceeds of $2,253,729.20.
A holder of GENI common stock filed a notice to sell shares under Rule 144. The filing covers 202,876 common shares, to be sold through Fidelity Brokerage Services LLC, with an aggregate market value of $2,253,729.20. These shares relate to a recent restricted stock vesting on 01/02/2026, received from the issuer as compensation on that date.
The notice identifies the intended trading market as the NYSE, with an approximate sale date of 01/05/2026. It also discloses that the same seller previously sold 400,673 common shares on 11/10/2025, generating $4,167,039.27 in gross proceeds. The filing reports that 214,097,454 common shares were outstanding for the issuer at the time referenced.
A holder of common stock has filed notice of intent to sell 162,737 shares under Rule 144. The shares have an aggregate market value of $1,763,526.91 and are to be sold through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of December 18, 2025.
All of these shares were acquired from the issuer as restricted stock vesting on multiple dates between January 3, 2023 and January 7, 2025 as compensation. The notice reports that 214,097,454 shares of this class were outstanding, providing context for the overall share count.
GENI shareholder filed a Rule 144 notice for the proposed sale of 9,414 common shares. The shares were acquired on 12/12/2025 through restricted stock vesting as compensation from the issuer and are planned to be sold through Fidelity Brokerage Services LLC on the NYSE around 12/15/2025, with an aggregate market value of $100,750.51. The issuer reported 214,097,454 common shares outstanding, giving context for the size of this planned transaction.
A holder of GENI common stock plans to sell 9,415 shares on the NYSE through Fidelity Brokerage Services LLC. The shares have an aggregate market value of 100,761.21, and shares outstanding are listed as 214,097,454.
These shares were acquired on 12/12/2025 through restricted stock vesting from the issuer as compensation, with payment also dated 12/12/2025. The approximate sale date is 12/15/2025. The person selling represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.
Genius Sports Limited reported the results of its 2025 Annual General Meeting of Shareholders held on December 10, 2025. A total of 195,422,891 ordinary shares, representing approximately 78.4% of the voting share capital as of November 5, 2025, were present or represented by proxy, indicating strong shareholder participation.
Shareholders approved the 2024 annual report and audited financial statements, with 194,596,645 votes in favor, and re-appointed Kenneth J. Kay and Kimberly Ann Bradley as Class I Directors with support of 98.50% and 99.42% of votes cast, respectively. Daniel Burns was also re-appointed as a Class I Director, but with a closer vote, receiving 57.05% of votes cast in favor and 42.38% against.
WithumSmith+Brown, PC was re-appointed as auditor for SEC filings for the financial year ending December 31, 2025, and BDO LLP was re-appointed for the Guernsey statutory accounts, each with over 99.8% support. Shareholders also passed an ordinary resolution authorising the board to determine the remuneration of each auditor, with 99.77% of votes cast in favor.
Genius Sports (GENI): Mark Locke filed Amendment No. 4 to Schedule 13G reporting beneficial ownership of 17,070,924 ordinary shares, representing 7.2% of the class. The filing lists sole voting and sole dispositive power over the same 17,070,924 shares and no shared powers.
The percentage is calculated based on 238,718,120 shares outstanding as of September 30, 2025, as referenced from an Exhibit to a Form 6-K. The date of event requiring the filing is September 30, 2025. The reporting person is Mark Locke, Chief Executive Officer of Genius Sports Limited.
Genius Sports (GENI): ownership update. Capital Research Global Investors filed an amended Schedule 13G reporting beneficial ownership of 7,869,105 shares of Genius Sports common stock, equal to 3.3% of the class as of September 30, 2025. The filer has sole voting and sole dispositive power over these shares. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Genius Sports Limited (GENI): Wellington Management Group LLP and affiliates filed a Schedule 13G reporting beneficial ownership of 13,513,537 shares, or 5.63% of GENI common stock, as of 09/30/2025.
The filing lists shared voting power over 9,970,627 shares and shared dispositive power over 13,513,537 shares, with no sole voting or dispositive power. The securities are owned of record by clients of Wellington’s investment adviser subsidiaries.
The certification states the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing also notes no single client is known to have rights over more than five percent of the class.
GENI — Form 144 notice of proposed sale. A holder notified intent to sell 131,608 common shares through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $1,368,736.36. The approximate sale date is 11/10/2025.
The shares were acquired on 11/07/2025 via restricted stock vesting from the issuer, classified as compensation, in the same amount of 131,608. The table also lists 214,097,454 shares outstanding; this is a baseline figure, not the amount being offered.